◎ Sugi Atlas

Atlas / Drug / Triamcinolone

Triamcinolone

drug
On this page

Also known as AristocortDelphicortKenacortNSC-13397TriamcinolonaVolonSID50103941SID855586SID90341396SID47193900SID26751455SID50103942SID77851SID170465188SID144204885SID144210498

Summary

Triamcinolone (CHEMBL1451) is an approved small-molecule anti-allergic agent (ATC H02AB08) targeting NR3C1; indicated across 40 conditions including obstructive lung disease and eye disorder.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: H02AB08 (+7 more)
  • Targets: 1 (NR3C1)
  • Indications: 40 conditions
  • Clinical trials: 131
  • Chemistry: 394.4 Da · C21H27FO6

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1451
NameTriamcinolone
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID31307
ChEBICHEBI:9667
ATCH02AB08, R03BA06, R01AD11, D07XB02, S01BA05, C05AA12, D07AB09, A01AC01
Molecular formulaC21H27FO6
Molecular weight394.4
InChIKeyGFNANZIMVAIWHM-OBYCQNJPSA-N

SMILES: C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@H]([C@@]2(C(=O)CO)O)O)CCC4=CC(=O)C=C[C@@]43C)F)O

IUPAC name: (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one

ChEBI definition: A C21-steroid hormone that is 1,4-pregnadiene-3,20-dione carrying four hydroxy substituents at positions 11β, 16α, 17α and 21 as well as a fluoro substituent at position 9. Used in the form of its 16,17-acetonide to treat various skin infections.

Pharmacological roles (ChEBI): anti-allergic agent, anti-inflammatory drug.

Also known as: Aristocort, Delphicort, Kenacort, NSC-13397, Triamcinolona, Triamcinolone, Volon, triamcinolone, SID50103941, SID855586, SID90341396, TRIAMCINOLONE

Patent coverage: 21,491 distinct patent families (81,668 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
NR3C1Glucocorticoid receptorAgonist7.70.9%P04150

Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Prelamin-A/C, RecQ-like DNA helicase BLM, Peripheral myelin protein 22, Glucocorticoid receptor, Progesterone receptor, Nuclear factor NF-kappa-B p105 subunit, Cytochrome P450 3A4, Cytochrome P450 2J2, 3-hydroxyacyl-CoA dehydrogenase type-2, Hypoxia-inducible factor 1-alpha.

Bioactivity

ChEMBL activities: 12 potent at pChembl ≥ 5 of 18 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
BLM8.35Potency4.5nMCHEMBL_ACT_4753929
BLM8.35Potency4.5nMCHEMBL_ACT_4945889
NR3C18.04AC509.1nMCHEMBL_ACT_25175433
LMNA7.65Potency22.4nMCHEMBL_ACT_3665947
NR3C17.58Ki26nMCHEMBL_ACT_7782660
NFKB17.55Potency28.2nMCHEMBL_ACT_3671996
NFKB17.55Potency28.2nMCHEMBL_ACT_4585278
HIF1A7.5Potency31.6nMCHEMBL_ACT_4117637
HIF1A7.5Potency31.6nMCHEMBL_ACT_4519688
NR3C17.24IC5058nMCHEMBL_ACT_7782659
NR3C15.92AC501200nMCHEMBL_ACT_25115947
CYP2J25.02IC509470nMCHEMBL_ACT_15461590

Target pathways

Aggregated over 1 target gene(s): NR3C1.

Top Reactome pathways

8 total, by targets touching each:

PathwayTargetsGenes
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand1NR3C1
Nuclear Receptor transcription pathway1NR3C1
SUMOylation of intracellular receptors1NR3C1
PTK6 Expression1NR3C1
Regulation of RUNX2 expression and activity1NR3C1
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes1NR3C1
Potential therapeutics for SARS1NR3C1
Regulation of NPAS4 gene transcription1NR3C1

Dominant GO biological processes

GO termTargets
negative regulation of transcription by RNA polymerase II1
regulation of gluconeogenesis1
chromatin organization1
regulation of DNA-templated transcription1
regulation of transcription by RNA polymerase II1
apoptotic process1
chromosome segregation1
signal transduction1
glucocorticoid metabolic process1
response to wounding1
gene expression1
microglia differentiation1
adrenal gland development1
nuclear receptor-mediated steroid hormone signaling pathway1
regulation of glucocorticoid biosynthetic process1

Indications & clinical

Indications

40 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
obstructive lung disease4MONDO:0002267HP:0006536
eye disorder4MONDO:0005328EFO:0005752
hemorrhoid4MONDO:0004872EFO:0009552
skin disorder4MONDO:0005093EFO:0000701
chronic pancreatitis3MONDO:0005003EFO:0000342
keloid3MONDO:0005348EFO:0004212
chronic obstructive pulmonary disease3MONDO:0005002EFO:0000341
allergic rhinitis3MONDO:0011786EFO:0005854
retinal vein occlusion3MONDO:0006951EFO:1001157
perennial allergic rhinitis3MONDO:0024332EFO:1001417
radiculopathy3MONDO:0002959MONDO:0002959
osteoarthritis, hip3MONDO:0006629EFO:1000786
corneal edema3MONDO:0006712EFO:1000879
orbital pseudotumor3MONDO:0004769EFO:1001077
osteoarthritis3MONDO:0005178MONDO:0005178
lung disorder3MONDO:0005275EFO:0003818
vitiligo2MONDO:0008661EFO:0004208
osteoarthritis, knee2MONDO:0005416EFO:0004616
atopic eczema2MONDO:0004980EFO:0000274
melanoma2MONDO:0005105EFO:0000756
vascular disorder2MONDO:0005385EFO:0004264
psoriasis2MONDO:0005083EFO:0000676
lichen planus, oral2MONDO:0043923EFO:0008517
wet macular degeneration2MONDO:0005417EFO:0004683
alopecia areata2MONDO:0005340EFO:0004192
acneiform dermatitis2MONDO:0006521EFO:1000662
nasal cavity polyp1MONDO:0006314EFO:1000391
diabetic retinopathy1MONDO:0005266EFO:0003770
age-related macular degeneration1MONDO:0005150EFO:0001365
anterior ischemic optic neuropathy1MONDO:0006649EFO:1000809
rotator cuff syndrome1MONDO:0007028EFO:1001250
sinusitis0MONDO:0005961EFO:0007486
neuralgia0MONDO:0021667EFO:0005762

7 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 131.

Phase distribution

PhaseTrials
Not specified39
PHASE438
PHASE318
PHASE214
PHASE2/PHASE310
EARLY_PHASE15
PHASE1/PHASE24
PHASE13

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05336968PHASE4RECRUITINGTriamcinolone Ketorolac (TriKe) Knee Trial
NCT07276802PHASE4NOT_YET_RECRUITINGThe TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)
NCT07352566PHASE4NOT_YET_RECRUITINGUtilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT07494136PHASE4NOT_YET_RECRUITINGDose Dependent Steroid Injections
NCT00566761PHASE4TERMINATEDTreatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO
NCT00682539PHASE4COMPLETEDIntraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema
NCT00731289PHASE4COMPLETEDGait Patterns After Intraarticular Treatment of Patients With Osteoarthritis of the Knee
NCT00737971PHASE4COMPLETEDEfficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema
NCT00826462PHASE4COMPLETEDTreatment Study of Steroid Injection and Physical Therapy for Acute Lateral Epicondylitis
NCT01295099PHASE4WITHDRAWNKeloid Scarring: Treatment and Pathophysiology
NCT01335321PHASE4COMPLETEDEvaluation of the Effect of Adding Corticosteroid to Viscosupplementation
NCT01420471PHASE4COMPLETEDMedicated Punctured-Glove-Finger Spacer Study
NCT01801774PHASE4UNKNOWNEfficacy Comparison Study of Steroids to Control Post-operative Inflammation
NCT01995045PHASE4COMPLETEDPostoperative Pain Control Following Vitreoretinal Surgery
NCT02024724PHASE4COMPLETEDUltrasound Guided Trigeminal Nerve Block for Typical or Atypical Facial Pain
NCT02095197PHASE4COMPLETEDC7-T1 Epidural Steroid Injections Versus Targeted Injection for Treatment of Cervical Radicular Pain
NCT02155439PHASE4COMPLETEDTreatment of Keloidscars With Intralesional Triamcinolone and 5-fluorouracil Injections-prospective, Randomized, Controlled Trial - Pilot Study
NCT02317276PHASE4TERMINATEDA Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal
NCT02398539PHASE4UNKNOWNSilver Nitrate Application and Topical Corticosteroids for Hypergranulation Tissue
NCT02451748PHASE4COMPLETEDIL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA
NCT02655523PHASE4WITHDRAWNA Comparison of Dexamethasone and Triamcinolone for Ultrasound-guided Occipital C2 Nerve Blocks
NCT02748395PHASE4WITHDRAWNLidocaine and Triamcinolone vs Saline Trigger Point Injection for Treatment of Chronic Abdominal Wall Pain
NCT02949466PHASE4UNKNOWNAdditional Effects of Triamcinolone to Hyaluronic Acid on Knee Osteoarthritis
NCT03090698PHASE4UNKNOWNOutcomes of Injections in Patients Waiting for Total Knee Replacement
NCT03241563PHASE4COMPLETEDSubcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for Reduction of Submental Fat
NCT03273036PHASE4COMPLETEDPerioperative Outcome of Corticosteroids in Transforaminal Endoscopic Lumbar Discectomy
NCT03407027PHASE4UNKNOWNEfficacy of Corticoid Infiltration in Quadratus Lumborum Syndrome
NCT03586687PHASE4TERMINATEDOsteoarthritis Shoulder Injection Study
NCT03641508PHASE4COMPLETEDLong Term Effectiveness of Trigger Finger Injections With Triamcinolone vs. Dexamethasone
NCT03797872PHASE4COMPLETEDPsoriatic Oligoarthritis Intervention With Symptomatic thErapy
NCT03832010PHASE4COMPLETEDSteroid-reducing Effects of Crisaborole
NCT03901768PHASE4UNKNOWNEffects of Combined Topical and Systemic Steroid Administrations on Better Early Postoperative Pain Management in Total Knee Arthroplasty
NCT03982862PHASE4UNKNOWNBotulinum Toxins Intralesional Injection for Scar Pain
NCT04361513PHASE4COMPLETEDGenicular Nerve Block in Rheuamtoid Arthritis
NCT05364099PHASE4WITHDRAWNSuprascapular Nerve Block for Treatment of Shoulder Pain in Individuals With Spinal Cord Injuries
NCT05660694PHASE4COMPLETEDComparison of Triamcinolone With Pentoxifylline and Vitamin- E Efficacy in the Treatment of Stage 2 and 3 Oral Submucous Fibrosis
NCT05792111PHASE4UNKNOWNCaudal Epidural Steroid and Trigger Point Injection
NCT05997238PHASE4COMPLETEDEvaluation of the Effect of Triamcinolone at Different Doses on LIA During TKA
NCT02025023PHASE3RECRUITINGLocal 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
NCT04990128PHASE3NOT_YET_RECRUITINGBone Marrow Aspirate Concentrate Versus Triamcinolone Injection For Hip Osteoarthritis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 3 clinical and 2 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

173 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
FULVESTRANTChEMBL + PubChemPhase 4 (approved)NR3C1
PODOFILOXChEMBL + PubChemPhase 4 (approved)NR3C1
REGORAFENIBChEMBL + PubChemPhase 4 (approved)NR3C1
ACENOCOUMAROLChEMBLPhase 4 (approved)NR3C1
ALCLOMETASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
AMCINONIDEChEMBLPhase 4 (approved)NR3C1
AMIODARONEChEMBLPhase 4 (approved)NR3C1
APREPITANTChEMBLPhase 4 (approved)NR3C1
AURANOFINChEMBLPhase 4 (approved)NR3C1
BAZEDOXIFENEChEMBLPhase 4 (approved)NR3C1
BECLOMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
BENZBROMARONEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE PHOSPHORIC ACIDChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE VALERATEChEMBLPhase 4 (approved)NR3C1
BUDESONIDEChEMBLPhase 4 (approved)NR3C1
BUTOCONAZOLEChEMBLPhase 4 (approved)NR3C1
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)NR3C1
CANRENONEChEMBLPhase 4 (approved)NR3C1
CHLORMADINONEChEMBLPhase 4 (approved)NR3C1
CICLESONIDEChEMBLPhase 4 (approved)NR3C1
CLOBETASOL PROPIONATEChEMBLPhase 4 (approved)NR3C1
CLOFAZIMINEChEMBLPhase 4 (approved)NR3C1
CLOTRIMAZOLEChEMBLPhase 4 (approved)NR3C1
CORTISONEChEMBLPhase 4 (approved)NR3C1
DANAZOLChEMBLPhase 4 (approved)NR3C1
DAUNORUBICINChEMBLPhase 4 (approved)NR3C1
DEFLAZACORTChEMBLPhase 4 (approved)NR3C1
DESOGESTRELChEMBLPhase 4 (approved)NR3C1
DESONIDEChEMBLPhase 4 (approved)NR3C1
DESOXIMETASONEChEMBLPhase 4 (approved)NR3C1
DESOXYCORTICOSTERONE PIVALATEChEMBLPhase 4 (approved)NR3C1
DEXAMETHASONEChEMBLPhase 4 (approved)NR3C1
DEXTROTHYROXINEChEMBLPhase 4 (approved)NR3C1
DIENESTROLChEMBLPhase 4 (approved)NR3C1
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)NR3C1
DIFLORASONE DIACETATEChEMBLPhase 4 (approved)NR3C1
DOXORUBICINChEMBLPhase 4 (approved)NR3C1
DROSPIRENONEChEMBLPhase 4 (approved)NR3C1
ECONAZOLEChEMBLPhase 4 (approved)NR3C1
EFAVIRENZChEMBLPhase 4 (approved)NR3C1
ENZALUTAMIDEChEMBLPhase 4 (approved)NR3C1
EPLERENONEChEMBLPhase 4 (approved)NR3C1
ESTRADIOLChEMBLPhase 4 (approved)NR3C1
ESTRIOLChEMBLPhase 4 (approved)NR3C1
ETHINYL ESTRADIOLChEMBLPhase 4 (approved)NR3C1
EXEMESTANEChEMBLPhase 4 (approved)NR3C1
FELODIPINEChEMBLPhase 4 (approved)NR3C1
FLUDROCORTISONEChEMBLPhase 4 (approved)NR3C1
FLUNISOLIDEChEMBLPhase 4 (approved)NR3C1
FLUOCINOLONE ACETONIDEChEMBLPhase 4 (approved)NR3C1
FLUOCINONIDEChEMBLPhase 4 (approved)NR3C1
FLUOROMETHOLONEChEMBLPhase 4 (approved)NR3C1
FLUOXYMESTERONEChEMBLPhase 4 (approved)NR3C1
FLURANDRENOLIDEChEMBLPhase 4 (approved)NR3C1
FLUTICASONE FUROATEChEMBLPhase 4 (approved)NR3C1
FLUTICASONE PROPIONATEChEMBLPhase 4 (approved)NR3C1
GLUCAGONChEMBLPhase 4 (approved)NR3C1
HALCINONIDEChEMBLPhase 4 (approved)NR3C1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot